Recombinant VWF Prophylactic Dosing for Severe VWD Bleeding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for von Willebrand Disease (VWD) primarily focus on replacement therapy for managing bleeding episodes, but there is a lack of effective prophylactic measures to prevent spontaneous bleeding episodes in patients.
Innovation Solution
Administering recombinant von Willebrand Factor (rVWF) at doses ranging from 40 IU/kg to 80 IU/kg twice weekly, potentially concomitantly or sequentially with recombinant Factor VIII, to reduce the frequency and duration of spontaneous bleeding episodes in patients with severe VWD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Force
If replacement therapy is used to manage bleeding episodes in VWD patients, then bleeding episodes can be treated after they occur, but there is no effective prophylactic measure to prevent spontaneous bleeding episodes in advance
Solution Approach 1:
The patent applies preliminary action by administering rVWF at prophylactic doses (40-80 IU/kg twice weekly) before spontaneous bleeding episodes occur. This preventive dosing schedule maintains adequate VWF activity levels in patients continuously, preventing bleeding episodes rather than treating them after onset, thereby resolving the contradiction between having treatment capability and lacking prevention capability
2Productivity
If plasma-derived VWF (pdVWF) is used for treatment, then bleeding episodes can be managed, but the treatment does not significantly reduce the annual bleeding rate compared to current standards
Solution Approach 1:
The patent applies parameter changes by modifying the dosing parameters of VWF replacement therapy: using recombinant VWF (rVWF) instead of plasma-derived VWF, administering at specific dose ranges (40-80 IU/kg), and using a twice-weekly dosing frequency. These parameter changes result in a significant reduction of the annual bleeding rate by 25% to 95% compared to conventional treatment, thereby resolving the contradiction between treatment efficacy and bleeding rate reduction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed method significantly reduces the annual bleeding rate by 25% to 95% in patients with severe VWD, improving VWF and FVIII activity levels and collagen-binding capacity, thereby effectively managing spontaneous bleeding episodes.
Implementation Method 1
Multimerized VWF binds to the platelet surface glycoprotein Gp1bα, through an interaction in the A1 domain of VWF, facilitating platelet adhesion
Implementation Method 2
VWF forms a bridge between the platelet and the vessel wall that is essential to platelet adhesion and primary hemostasis under conditions of high shear stress
Implementation Method 3
Normally, endothelial cells secrete large polymeric forms of VWF and those forms of VWF that have a lower molecular weight arise from proteolytic cleavage
Implementation Method 4
Multimeric forms of VWF are composed of 250 kD polypeptide subunits linked together by disulfide bonds
Data Source
AI summary
The present invention relates to a method for prophylactic treatment of spontaneous bleeding in a subject with severe von Willebrand Disease comprising administering a therapeutic amount of recombinant von Willebrand Factor (rVWF) to the subject.